Collegium Reports Fourth Quarter and Full-Year 2021 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/4/2026
- Wall Street ends sharply higher as Waller remarks ease rate hike fears
- Fed’s Waller open to September rate hold - if disinflation holds up
- Broadcom raises AI chip forecast as Big Tech keeps writing bigger checks
- Nvidia to acquire AI platform Hugging Face in landmark $12.9B deal
- Tesla to unveil Cybercab Texas today, details are few
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
Collegium Pharma (COLL) Misses Q4 EPS by $1.77
February 24, 2022 4:30 PM ESTCollegium Pharma (NASDAQ: COLL) reported Q4 EPS of ($0.73), $1.77 worse than the analyst estimate of $1.04. Revenue for the quarter came in at $27.36 million versus the consensus estimate of $81.61 million.
For earnings history and earnings-related data on Collegium Pharma (COLL) click here.
... More